{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:02:03Z","timestamp":1777874523567,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7759\/cureus.108047","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:55:59Z","timestamp":1777578959000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary Cutaneous Anaplastic Large Cell Lymphoma Mimicking Pyoderma Gangrenosum: An Atypical Presentation and Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Mossaab","family":"El Mousadik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Tazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monsif","family":"Fadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najat","family":"Lamalmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouama","family":"Bouanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze R","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019, 133:1703-1714. 10.1182\/blood-2018-11-881268","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5114\/dr.2023.138937","article-title":"Primary cutaneous lymphomas. Diagnostic and therapeutic guidelines of the Polish Dermatological Society (PTD) and Polish Lymphoma Research Group (PLRG)","volume":"110","author":"Soko\u0142owska-Wojdy\u0142o M","year":"2023","unstructured":"Soko\u0142owska-Wojdy\u0142o M, Olszewska B, Chmielowska E, et al.. Primary cutaneous lymphomas. Diagnostic and therapeutic guidelines of the Polish Dermatological Society (PTD) and Polish Lymphoma Research Group (PLRG). Dermatol Rev. 2023, 110:647-674. 10.5114\/dr.2023.138937","journal-title":"Dermatol Rev"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk MW","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC, et al.. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000, 95:3653-3661.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7560.181","article-title":"Diagnosis and treatment of pyoderma gangrenosum","volume":"333","author":"Brooklyn T","year":"2006","unstructured":"Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006, 333:181-184. 10.1136\/bmj.333.7560.181","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze R","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:iv30-iv40. 10.1093\/annonc\/mdy133","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan M","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009, 50:1257-1260. 10.1080\/10428190903040048","journal-title":"Leuk Lymphoma"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00221-6","article-title":"Pyoderma gangrenosum","volume":"6","year":"2020","unstructured":"Pyoderma gangrenosum. Nat Rev Dis Primers. 2020, 6.80. 10.1038\/s41572-020-00221-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12547","article-title":"ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course","volume":"42","author":"Wehkamp U","year":"2015","unstructured":"Wehkamp U, Oschlies I, Nagel I, et al.. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. J Cutan Pathol. 2015, 42:870-877. 10.1111\/cup.12547","journal-title":"J Cutan Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014, 32:3059-3068. 10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim YH","year":"2007","unstructured":"Kim YH, Willemze R, Pimpinelli N, et al.. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007, 110:479-484. 10.1182\/blood-2006-10-054601","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1343","article-title":"CD30\/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group","volume":"13","author":"Paulli M","year":"1995","unstructured":"Paulli M, Berti E, Rosso R, et al.. CD30\/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995, 13:1343-1354. 10.1200\/JCO.1995.13.6.1343","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince HM","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, et al.. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017, 390:555-566. 10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz SM","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, et al.. T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022, 20:285-308. 10.6004\/jnccn.2022.0015","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/488663-primary-cutaneous-anaplastic-large-cell-lymphoma-mimicking-pyoderma-gangrenosum-an-atypical-presentation-and-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:56:00Z","timestamp":1777578960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/488663-primary-cutaneous-anaplastic-large-cell-lymphoma-mimicking-pyoderma-gangrenosum-an-atypical-presentation-and-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.108047","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}